scholarly journals Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation

2017 ◽  
Vol 18 (4) ◽  
pp. 907-915 ◽  
Author(s):  
Scott Davis ◽  
Jane Gralla ◽  
Patrick Klem ◽  
Suhong Tong ◽  
Gina Wedermyer ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Therapeutic Range ◽  
De Novo ◽  
First Year ◽  
Specific Antibodies ◽  
Time In Therapeutic Range ◽  
Donor Specific Antibodies

scholarly journals Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor–Specific Antibodies

2020 ◽  
Vol 104 (4) ◽  
pp. 881-887 ◽  
Author(s):  
Scott Davis ◽  
Jane Gralla ◽  
Patrick Klem ◽  
Erik Stites ◽  
Alexander Wiseman ◽  
...  
Keyword(s):  
Therapeutic Range ◽  
De Novo ◽  
Specific Antibodies ◽  
Time In Therapeutic Range ◽  
Intrapatient Variability ◽  
Donor Specific Antibodies

scholarly journals Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249934
Author(s):  
Dominique Bertrand ◽  
Rangolie Kaveri ◽  
Charlotte Laurent ◽  
Philippe Gatault ◽  
Maïté Jauréguy ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Prognostic Value ◽  
De Novo ◽  
Added Value ◽  
Multicentric Study ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Single Antigen ◽  
Donor Specific Antibodies ◽  
Allograft Loss

De novo donor-specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and allograft loss. We tested Immucor* (IM) Luminex Single-antigen beads (LSAB) assay and C3d-fixing antibodies in the setting of dnDSA and subclinical (s) ABMR. This retrospective multicentric study included 123 patients biopsied because of the presence of subclinical de novo DSA detected by One Lamda* Labscreen (MFI > 1000). In 112 patients, sera of the day of the biopsy were available and tested in a central lab with IM Lifecodes LSAB and C3d fixing antibodies assays. In 16 patients (14.3%), no DSA was detected using Immucor test. In 96 patients, at least one DSA was determined with IM. Systematic biopsies showed active sABMR in 30 patients (31.2%), chronic active sABMR in 17 patients (17.7%) and no lesions of sABMR in 49 KT recipients (51%). Intensitity criteria (BCM, BCR and AD-BCR) of DSA were not statistically different between these 3 histological groups. The proportion of patients with C3d-fixing DSA was not statistically different between the 3 groups and did not offer any prognostic value regarding graft survival. Performing biopsy for dnDSA could not be guided by the intensity criteria of IM LSAB assay. C3d-fixing DSA do not offer added value.

CLINICAL SIGNIFICANCE OF DE NOVO PRODUCTION OF HLA DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANTATION.

2010 ◽  
Vol 90 ◽  
pp. 272
Author(s):  
A. Piazza ◽  
E. Poggi ◽  
G. Ozzella ◽  
D. Caputo ◽  
R. Cremona ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Clinical Significance ◽  
De Novo ◽  
Specific Antibodies ◽  
Donor Specific Antibodies
Sign in / Sign up

Export Citation Format

Share Document